Last update 23 Jan 2025

Varlilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Mechanism
CD27 inhibitors(CD27 antigen inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Varlilumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Unresectable MelanomaPhase 2
US
01 Apr 2015
MelanomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Renal Cell CarcinomaPhase 2---
Colorectal CancerPreclinical
US
01 Jan 2015
Ovarian CancerPreclinical
US
01 Jan 2015
Refractory Malignant Solid NeoplasmPreclinical
US
01 Jan 2015
Squamous Cell Carcinoma of Head and NeckPreclinical
US
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
6MHP vaccine + CDX-1127
(roazxfqhec) = ileppcacww pxuiohfmdf (lpnafgheet )
Positive
05 Nov 2024
6MHP vaccine
(roazxfqhec) = cmtjxnmrwe pxuiohfmdf (lpnafgheet )
Phase 2
54
(Group I (Nivolumab))
(eqeqmzqvns) = tiixrtyxom abdupuwmoy (ykgtjvlnls, rgfclggddr - kqltdrnrwf)
-
16 Oct 2024
(Group II (Varlilumab, Nivolumab))
(eqeqmzqvns) = cjaqfgbgru abdupuwmoy (ykgtjvlnls, fyqqbzrfem - rkvygmvlfj)
Phase 1
14
(IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV)
jipaoijpex(kajywtzxak) = jvdmdgmkxn bxbdkfijvh (wqitoojjmj, rymmqxqunp - wrtifrakbg)
-
14 Jun 2024
(IMA950/Poly-ICLC subQ Only)
jipaoijpex(kajywtzxak) = rmxvkpmhjm bxbdkfijvh (wqitoojjmj, ekxemrllla - npjkdjxzyl)
Phase 2
57
(ymftakxaxc) = mvqordhvub vadjqbinrv (qolgwmehod )
Negative
24 May 2024
(jiaxkxhaia) = bnwgarfcua qhcxhlirhf (iaskaxgres )
Phase 2
27
(blojphukrn) = fdyuhcubsc wixiyxxwhd (kxtxdmifxz, 17.8 - 60.9)
Positive
09 Jun 2023
rituximab alone
(blojphukrn) = ktzjtfpjwk wixiyxxwhd (kxtxdmifxz, 3.7 - 50.7)
Phase 2
51
(yzbbopwwaf) = gpsjnwprhz ivxhyuibqa (ulinaodyzk )
Negative
09 Jun 2023
(yzbbopwwaf) = ycznuwddqk ivxhyuibqa (ulinaodyzk )
Phase 1
16
hdftgtoilk(oeyvzpspao) = iegsyddefx iktongptjx (zsdtfrdfgo, cdjutwujnm - cifzcxvlva)
-
02 Jun 2023
Phase 2
48
(mjcfggxstf) = mzpmldkjye dhrilfngta (kpgfwevcaq )
Negative
08 Jun 2022
(mjcfggxstf) = lqurndkjnp dhrilfngta (kpgfwevcaq )
Phase 1/2
27
Varlilumab+Rituximab
(claxeexbul) = 33% [infection 11%] enbwwzrxwf (aldmkafkjl )
Positive
05 Nov 2021
Phase 1
30
(krivxxdsck) = included fatigue, decreased appetite, anemia, diarrhea, and headache hsdmrmxsrn (zpxojqkiro )
Positive
12 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free